Researchers aimed to determine the predictors of 30-day readmission following total hip or knee arthroplasty among patients with systemic lupus erythematosus.

Writing assistance was utilized in the production of this manuscript. Cite this: Roflumilast: Systemic Therapy for Chronic Obstructive Pulmonary Disease - Medscape - Oct 01, 2008.

Only five days after FDA approval of Yutrepia, Liquidia announced its first commercial shipment of the therapy, making prescriptions available to patients at specialty pharmacies. “We have moved with ...

Panelists discuss how emerging, better-tolerated oral therapies for idiopathic pulmonary fibrosis (IPF) and progressive ...

For patients undergoing surgical procedures, there is no association between liberal preprocedural fasting policies and ...

Serious conditions behind bloody cough symptoms revealed. Life-threatening diseases that cause alarming blood in cough ...

Three Phase 1 studies support once-daily inhaled administration of mosliciguat with no evidence of serious systemic side effects Results informed the ongoing Phase 2 PHocus study of mosliciguat for ...

Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced the receipt of an additional $50.0 ...

Gunnarsson K, et al. Hematological malignancies in systemic sclerosis, a population-based nationwide register study. Presented at EULAR 2025; OP0221. DOI: 10.1136/annrheumdis-2025-eular.B444.

Previous knowledge on melatonin use for pulmonary arterial hypertension has primarily been gathered from animal studies, with ...

Dr. Kimberly Trotter distilled four high-impact disease clusters—gout, rheumatoid arthritis (RA), systemic lupus ...